Literature DB >> 8491969

Hyperdynamic state in chronic liver diseases.

R J Groszmann1.   

Abstract

Reduced splanchnic arteriolar resistance and increased portal venous outflow have been associated with chronic portal hypertension. This hyperdynamic splanchnic circulatory state is accompanied by a hyperdynamic systemic circulation characterized by a high cardiac index and low systemic vascular resistance. The systemic phenomenon occurs earlier than the regional one, possibly because the increased outflow resistance induced by portal hypertension delays the effect of circulating humoral vasodilators on the splanchnic bed. Several vasoactive substances have been advanced as the vasodilator responsible for the hyperdynamic circulation. Glucagon and bile acids have been found to be potent splanchnic vasodilators in animal studies. However, neither consistently dilates other vascular beds. For example, bile acids are splanchnic--but not systemic--vasodilators. Several studies suggest a role in chronic liver disease for nitric oxide, a potent endogenous vasodilator secreted by endothelial cells. Prostaglandins have also been proposed as the responsible vasodilator. However, mixed results have been seen with experimental suppression of prostaglandin synthesis. For a hyperdynamic state to develop and persist requires not only reduced cardiac afterload, but also an increased venous return. Recently, we found an expanded plasma volume after initial vasodilation in rats with portal hypertension. This 'refill' of the circulation may be intrinsic to development of the hyperdynamic state. Furthermore, this blood volume expansion may be the link between vasodilation and the hyperdynamic circulation.

Entities:  

Mesh:

Year:  1993        PMID: 8491969     DOI: 10.1016/s0168-8278(05)80454-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Enhanced vascular responses to noradrenaline in isolated omental arteries from patients with advanced cirrhosis: evidence against intrinsic vascular hyporeactivity in cirrhosis.

Authors:  R B Vaughan; P W Angus; J A Angus
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 2.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

3.  Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites.

Authors:  J W Ferguson; A R Dover; S Chia; N L M Cruden; P C Hayes; D E Newby
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 4.  Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Investig       Date:  1994-08

5.  Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation.

Authors:  R B Vaughan; P W Angus; J P F Chin-Dusting
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

6.  Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results.

Authors:  J M Rodríguez-Laiz; R Bañares; A Echenagusia; M Casado; F Camuñez; F Pérez-Roldán; A de Diego; E Cos; G Clemente
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

Review 7.  Variceal bleeding : pharmacological treatment and prophylactic strategies.

Authors:  Cándid Villanueva; Joaquim Balanzó
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.

Authors:  N A Mohammed; S A Abd El-Aleem; H A El-Hafiz; R F T McMahon; S A El-Aleem
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.